@article{edfea2c8a9944b51bb4763093fe8147b,
title = "Comparison of a soluble co-formulation of insulin degludec/insulin aspart vs biphasic insulin aspart 30 in type 2 diabetes: a randomised trial",
abstract = "Insulin degludec/insulin aspart (IDegAsp) is a soluble co-formulation of insulin degludec (70%) and insulin aspart (IAsp: 30%). Here, we compare the efficacy and safety of IDegAsp, an alternative IDegAsp formulation (AF: containing 45% IAsp), and biphasic IAsp 30 (BIAsp 30).",
keywords = "Adolescent, Adult, Aged, Biphasic Insulins, Chemistry, Pharmaceutical, Diabetes Mellitus, Type 2, Drug Administration Schedule, Drug Combinations, Female, Hemoglobin A, Glycosylated, Humans, Hypoglycemic Agents, Insulin Aspart, Insulin, Isophane, Insulin, Long-Acting, Male, Metformin, Middle Aged, Solubility, Treatment Outcome, Young Adult",
author = "Leo Niskanen and Leiter, {Lawrence A} and Edward Franek and Jianping Weng and Taner Damci and Manuel Mu{\~n}oz-Torres and Jean-Paul Donnet and Lars Endahl and Skj{\o}th, {Trine Vang} and Allan Vaag",
year = "2012",
doi = "10.1530/EJE-12-0293",
language = "English",
volume = "167",
pages = "287--94",
journal = "European Journal of Endocrinology",
issn = "0804-4643",
publisher = "BioScientifica Ltd",
number = "2",
}